JP Morgan Downgrades Amdocs to Neutral, Lowers Price Target to $86

JP Morgan analyst Jackson Ader downgrades Amdocs (NASDAQ:DOX) from Overweight to Neutral and lowers the price target from $91 to $86.

byBenzinga Newsdesk

December 14, 2021

1 minute read

JP Morgan analyst Jackson Ader downgrades Amdocs (NASDAQ:DOX) from Overweight to Neutral and lowers the price target from $91 to $86.

How Much Did Andy Jassy Make In His First Year As Amazon CEO?

By Chris Katje

Today, 6:37 AM

The CEO of e-commerce giant Amazon.com was the recipient of a prime compensation package in his first year leading the company. Here’s how much Andy Jassy made in 2021.

AMZN

The Past Week’s Notable Insider Buys Included Asana, Designer Brands, Evergy And More

By Nelson Hem

Today, 6:37 AM

Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain. The week's most notable insider purchases were made by returning buyers. A chief executive officer and an executive board chair were among the notable insiders adding to their stakes.

ADI

Healx, Ovid Therapeutics To Enter Strategic Partnership; Terms Not Disclosed

By Benzinga Newsdesk

Today, 6:37 AM

Ovid Therapeutics (NASDAQ:OVID) ("Ovid"), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, and Healx, the AI-powered,

OVID